DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating ...

Dependable recurring dividends from quality, high-yield stocks like these five are a recipe for passive income success.